Abstract
The present invention provides a combination of (i) an immune checkpoint modulator and (ii) an ATP hydrolyzing enzyme, a nucleic acid encoding an ATP hydrolyzing enzyme, or host cells, microorganisms or viral particles comprising such nucleic acids encoding an ATP hydrolyzing enzyme. The combination may be used in medicine, in particular in the treatment of cancer, for example in cancer immunotherapy.
Full Text
What is claimed is:
The present invention provides a combination of (i) an immune checkpoint modulator and (ii) an ATP hydrolyzing enzyme, a nucleic acid encoding an ATP hydrolyzing enzyme, or host cells, microorganisms or viral particles comprising such nucleic acids encoding an ATP hydrolyzing enzyme. The combination may be used in medicine, in particular in the treatment of cancer, for example in cancer immunotherapy.
Timeline
Filed
05/22/2026Published
09/10/2026Granted
Not AvailableIPC Codes(7)
C07K 16/28:against receptors, cell surface antigens or cell surface determinants
A61K 9/00:Medicinal preparations characterised by special physical form
A61K 39/00:Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N 33/53)